Tilray to expand presence in Italy through partnership

Executive Summary

• Tilray Medical’s subsidiary, FL Group SRL, has entered into a strategic partnership with Italian pharmaceutical firm L. Molteni & C. dei F.lli Alitti Societa di Esercizio SpA to broaden access to medical cannabis extracts in Italy.
• The collaboration leverages Molteni’s network of pharmaceutical, scientific, and medical professionals to provide targeted education on medical cannabis therapies, specifically for pain management and substance dependence.
• Tilray Medical aims to combine its regulatory and distribution capabilities with Molteni’s scientific leadership to expand the availability of EU-GMP-certified cannabis therapies across Italy.

Key Details

• Parties Involved: Tilray Medical (via wholly owned subsidiary FL Group SRL) and L. Molteni & C. dei F.lli Alitti Societa di Esercizio SpA (Italian pharmaceutical firm).
• Objective: To broaden the availability of Tilray Medical cannabis extracts for patients across Italy and prioritize medical cannabis education for pain therapies.
• Molteni’s Role: Providing targeted education on medical cannabis therapies through its comprehensive network of pharmaceutical, scientific, and medical professionals throughout Italy.
• Tilray’s Role: Providing regulatory and distribution capabilities for EU-GMP-certified cannabis therapies.
• Strategic Context: Tilray Medical continues to lead the European medical cannabis market with operations in Germany, Italy, Portugal, Poland, and the United Kingdom.
• Company Background: Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments in 20 countries and across five continents.

Notable Quotes

• "This partnership reflects our commitment to advancing patient care through strategic collaboration," said Rajnish Ohri, managing director, international, at Tilray Brands. "By combining FL Group's regulatory and distribution capabilities with Molteni's scientific leadership, we are not only expanding access to high-quality, EU-GMP-certified cannabis therapies for patients across Italy but also prioritizing medical cannabis education for pain therapies. Through Molteni's extensive network of health care professionals, we aim to empower practitioners with the knowledge and resources needed to support patients seeking effective pain management solutions."